Treatment of Erysipelas in Children
Children with facial erysipelas or extensive involvement should be hospitalized for intravenous antibiotic therapy, while limited cases may be treated as outpatients with oral antibiotics targeting beta-hemolytic streptococci.
Initial Assessment and Hospitalization Criteria
Erysipelas in children requires careful risk stratification. Hospitalize children with:
- Facial involvement (unless quite limited)
- Extensive disease with fever and toxic appearance
- Any signs of systemic toxicity
The rationale for hospitalization in pediatric facial erysipelas is the historically high risk of Hemophilus influenzae infection and sepsis, though this pathogen is less common in the post-Hib vaccine era 1. The lower threshold for admission in children compared to adults reflects their higher risk of complications.
Antibiotic Selection
First-Line Therapy
Beta-lactam antibiotics are the mainstay of treatment, as erysipelas is predominantly caused by beta-hemolytic streptococci (groups A, B, C, and G):
- Inpatient: IV penicillin or first-generation cephalosporin
- Outpatient: Oral penicillin V, amoxicillin, or cephalexin
Penicillin remains highly effective because streptococcal resistance to penicillin is essentially nonexistent, despite emerging resistance to macrolides and clindamycin 2.
Alternative Agents
For penicillin-allergic patients:
- Macrolides (erythromycin, azithromycin) - though resistance concerns exist 2
- Clindamycin - effective but resistance reported 2
Coverage Considerations
While Staphylococcus aureus can occasionally cause erysipelas-like presentations, typical erysipelas with sharply demarcated borders is streptococcal. Do not routinely add MRSA coverage unless:
- Clinical features suggest staphylococcal infection (purulence, abscess)
- Failure to respond to beta-lactam therapy after 48-72 hours
- Culture data indicates staphylococcal involvement
The IDSA guidelines emphasize that nonpurulent cellulitis/erysipelas has a pathogen isolation rate <20%, making empiric streptococcal coverage appropriate 2.
Treatment Duration
Discharge criteria for hospitalized patients:
- Visible signs of clinical resolution
- Afebrile for at least 24 hours
- Transition to oral antibiotics for an additional 7-10 days at home 1
Recent evidence suggests shorter durations may be adequate (9-10 days total based on adult data) 3, but the traditional 10-14 day course remains standard in pediatrics given limited pediatric-specific data.
Common Pitfalls
- Avoid over-treating with broad-spectrum antibiotics: Erysipelas is a streptococcal infection; narrow-spectrum beta-lactams are appropriate and reduce resistance pressure
- Don't discharge too early: Children must be afebrile for 24 hours before transitioning to outpatient therapy 1
- Don't miss underlying risk factors: Look for entry portals (tinea pedis, trauma, eczema) that may require concurrent treatment 4
Monitoring and Follow-Up
Patients should show improvement within 48-72 hours of appropriate antibiotic therapy. Lack of response warrants:
- Reassessment of diagnosis (consider alternative diagnoses)
- Evaluation for complications (abscess formation, necrotizing infection)
- Culture if possible, though yield is low 2
- Consideration of antibiotic modification